HCP Cureblindness brings focus to avoidable vision loss for World Sight Day

News
Article

Every October, World Sight Day brings awareness to the global challenges of blindness and vision impairment

An AI-generated eye with a globe in the iris. Image credit: ©Real Fantasy Art – stock.adobe.com

"This World Sight Day, HCP is shining a light on why avoidable blindness can – and must – be overcome," said K-T Overbey, HCP's CEO. Image credit: ©Real Fantasy Art – stock.adobe.com

The Himalayan Cataract Project (HCP Cureblindness) recognizes World Sight Day by bringing attention to avoidable blindness worldwide. The project's mission is to to help individuals in developing countries retain and regain their sight.

World Sight Day is an annual day of awareness held the second Thursday in October. This year, HCP announced in a press release it will also be supporting the International Agency for the Prevention of Blindness (IAPB) #LoveYourEyes at Work campaign, which encourages workplace vision screenings globally.

Forty-three million people globally are blind, while another 295 million suffer from moderate-to-severe vision impairment, stated HCP in the release.1 Furthermore, 90% of these individuals live in low-to-middle income countries.

According to the release from HCP, vision loss causes over $400 billion in lost productivity annually and reduces employment. In people with blindness or moderate-to-severe vision impairment, overall reduction in employment is 30%. While the risk of premature mortality is 157% higher for people with blindness and 49% higher for people with vision loss that is moderate to severe or worse.

"This World Sight Day, HCP is shining a light on why avoidable blindness can – and must – be overcome," said K-T Overbey, HCP's CEO. "For more than 25 years, HCP has worked alongside a capable network of collaborators to help people globally retain and regain their sight by developing high-quality, cost-effective eye care systems in underserved areas of the world."

HCP states the solution lies in cataracts and corneal blindness awareness. “With early detection and treatment, the impact of many causes of blindness can be treated – and often cured – improving the quality of life for those individuals affected,” said the organization in the release.

According to the release1 almost half of all blindness is due to cataracts, and there are millions who suffer from corneal blindness which, in most cases, is preventable or treatable.

Reference:

  1. World Sight Day is October 12, 2023 - HCP Cureblindness Shines Light on Avoidable Blindness and Its Mission to Help Individuals in Underserved Countries Retain and Regain Their Sight. Press Release. Released October 5, 2023. Accessed October 9, 2023. https://www.prnewswire.com/news-releases/world-sight-day-is-october-12-2023---hcp-cureblindness-shines-light-on-avoidable-blindness-and-its-mission-to-help-individuals-in-underserved-countries-retain-and-regain-their-sight-301947960.html

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
© 2025 MJH Life Sciences

All rights reserved.